NICEM named after N.F. Gamalei (National Research Center for Epidemiology and Microbiology)
The main content of the center's activities is the solution of fundamental problems in the field of epidemiology, medical and molecular microbiology, infectious immunology. In these studies, a special place is occupied by general and particular patterns of the spread and epidemic manifestation of infectious diseases; structure and dynamics of infectious pathology of the population; emergence, functioning and epidemic manifestation of natural foci of human diseases; genetics, molecular biology, ecology and persistence of pathogens; problems of general and infectious immunology, including immunoregulation and immunocorrection, ways and means of diagnosing and preventing infectious diseases; biotechnology; nanotechnology.
The center is the basic organization of the country within the framework of the Scientific Council on the complex problem "Microbiology," coordinates the scientific activities of institutes and institutions of the relevant profile and carries out research programs on the epidemiology of infectious diseases and nosocomial infections, human natural diseases, medical microbiology, genetics and molecular biology of bacteria, theoretical and applied infectious immunology, biotechnology, nanotechnology.
History
2024
The government has allocated about ₽600 million to the Gamaleya Center for the purchase of medical equipment
On October 17, 2024, it became known that the Russian government decided to allocate ₽599,95 million from the reserve fund to the N.F. Gamaleya National Research Center for Epidemiology and Microbiology. The funds are intended for the purchase of equipment necessary to create the production of innovative drugs based on matrix ribonucleic acids (mRNA).
According to information provided by the press service of the Russian government, the allocated funds will allow you to purchase at least 41 units of specialized equipment. This equipment will be used to form the infrastructure for the production of new medicines, including for the treatment of cancer.
Prime Minister Mikhail Mishustin stressed the importance of this decision to organize timely patient therapy and reduce the dependence of Russian health care on foreign supplies. He noted that the new equipment will allow launching the production of the necessary drugs.
The decision on the development of technologies for the development of mRNA-based drugs was made in pursuance of the instructions of the President of Russia, given following a meeting with scientists on February 14, 2024.
The Ministry of Health of Russia is instructed to monitor the targeted and effective use of the allocated funds. The department must submit a corresponding report to the government by October 1, 2025.
The creation of the production of drugs based on mRNA technologies at the Gamaleya Center will be carried out in a full production cycle. This is the first stage in the development of this area in Russia, which opens up new prospects in the development and production of innovative medicines. The implementation of the project will speed up the development and production of new effective drugs for the treatment of various diseases, including cancer.[1]
Vaccine Release Agreement with OncoGenerix
On May 15, 2024, the Russian Direct Investment Fund (RDIF) announced a partnership with the Chinese company OncoGenerix, which has production facilities for the production of injectable drugs, with the aim of transferring technologies and production in China of a number of vaccines developed by the N.F. Gamalei. Read more here.
2023
Test of titanium implant coating technology for reconstructive surgery proposed by MISIS
The effectiveness of the titanium implant coating technology for reconstructive surgery previously proposed by NUST MISIS scientists was confirmed by specialists of the National Research Center for Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya. The results of in vivo tests showed that after special treatment, the interaction of the implant with bone tissue, its antibacterial and antifungal activity, is improved. This was announced on September 14, 2023 at the university. The technology does not require expensive equipment and can be carried out directly in hospitals and surgical centers. Read more here.
The murder of senior researcher Andrei Botikov
On March 3, 2023, it became known about the murder of Andrei Botikov, a senior researcher at the N.F. Gamaleya National Research Center for Epidemiology and Microbiology. This was reported by TASS and RIA Novosti, citing its sources in law enforcement agencies. Read more here.
2021
Scientists have found a way to reduce the cost of preclinical tests of bone implants
On April 7, 2021, it became known that scientists at NUST MISIS in tandem with biologists at the N.F. Gamaleya proposed an economical way to test the ingrowth strength of bone implants in case of critical skull defects. The method involves the use of a mouse model and allows evaluating the effectiveness of implant integration. The costs of using it are reduced by 50 times compared to experiments on large animals, allowing you to collect more extensive statistical material and accelerate the development of the clinical stage of research. The results of the work are published in the Journal of the Mechanical Behavior of Biomedical Materials. Read more here.
Receiving funding from the Ministry of Health in the amount of 25 million rubles for the development of new drugs and vaccines against COVID-19
As it became known at the end of January 2021, the Ministry of Health of the Russian Federation allocated tens of millions to the N.F. Gamaleya National Research Center for Epidemiology and Microbiology for the development of new drugs and vaccines against the coronavirus COVID-19.
In particular, about 25 million rubles are allocated from the federal budget for the creation of a vaccine, which will be based on a technology that is fundamentally different from that used in Sputnik V. A new immunobiological drug will be created using virus-like particles (VLP).
The amount of the subsidy for the implementation of all experimental scientific developments in 2021 was determined by the Ministry of Health at 274,457 thousand rubles, follows from Appendix 3 of the agreement. Based on the number of experimental developments that are included in the state task, about 25 million rubles can be allocated from the federal budget for the development of a new vaccine.
The completion of work on the creation of a new vaccine is scheduled for 2021, according to the state assignment of the Gamaleya Center (agreed by the Ministry of Health).
The document also refers to a budget of 41 million rubles for the development of new drugs for the treatment and prevention of COVID-19, then one of them will be created on the basis of a synthetic non-nucleotide inhibitor of the coronavirus protease. Its development and release are scheduled for 2021-2023.
The second drug can be used for both prevention and treatment of COVID-19. The drug is a blocker of the ACE2 receptor, with the help of which the coronavirus penetrates into the cells. The cost of experimental development is estimated at 25 million rubles. The work is planned to be completed in 2022.
At the end of January 2021, it also became known that the one-component Sputnik Light coronavirus vaccine will appear in February.[2]
2017
In 2017, it was renamed the National Research Center for Epidemiology and Microbiology named after Honorary Academician N.F. Gamalei.
2014
In 2014, it was transformed into the Federal Research Center for Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya (FNITSEM named after N.F. Gamaleya) by joining the D. I. Ivanovsky Research Institute of Virology.
2001
Since 2001, it was called the State Institution Research Institute of Epidemiology and Microbiology named after Honorary Academician N.F. Gamalei RAMS.
1919
1919 nationalized, transformed into the State (later - Central) Bacteriological Institute of the People's Commissariat of Health of the RSFSR.
1891: Foundation
It was founded in 1891 as the Private Chemical-Microscopic and Bacteriological Office of F. M. Blumenthal. Later transformed into the Private Chemical and Bacteriological Institute of Dr. F. M. Blumenthal. In
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |